118 related articles for article (PubMed ID: 31366526)
1. Chronic Myeloid Leukemia as Secondary Malignancy Following the Treatment of Hodgkin Lymphoma: A Case Series.
Millett R; Aggarwal A; Tabbara I; Nassereddine S
Anticancer Res; 2019 Aug; 39(8):4333-4335. PubMed ID: 31366526
[TBL] [Abstract][Full Text] [Related]
2. Chronic Myelogenous Leukemia Presenting as a Secondary Malignancy After BCR-ABL1-negative B-lymphoblastic Leukemia/Lymphoma in a Pediatric Patient.
Popa G; Blag C; Olteanu H
Pediatr Dev Pathol; 2017; 20(1):58-62. PubMed ID: 28276292
[TBL] [Abstract][Full Text] [Related]
3. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
4. Dual transcripts of
Nandagopalan SR; Kuila N; Biswas S; Pattnayak NC; Biswas G; Chakraborty S
Indian J Med Res; 2016 May; 143(Supplement):S136-S141. PubMed ID: 27748288
[TBL] [Abstract][Full Text] [Related]
5. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
6. Myeloid neoplasm with eosinophilia and BCR-JAK2/t(9;22)(p24;q11.2) morphologically mimicking chronic myeloid leukemia.
Thakral B; Muzzafar T; Wang SA; Medeiros LJ
Ann Diagn Pathol; 2020 Feb; 44():151405. PubMed ID: 31865248
[No Abstract] [Full Text] [Related]
7. Prolonged survival (17 years) in a patient with chronic myelogenous leukemia after therapy for Hodgkin's disease.
Salvagno L; Sorarú M; Leszl A; Koussis H; De Franchis G; Fiorentino MV
Leuk Lymphoma; 1994 Dec; 16(1-2):177-81. PubMed ID: 7696925
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma.
Alsop S; Sanger WG; Elenitoba-Johnson KS; Lim MS
Hum Pathol; 2007 Oct; 38(10):1576-80. PubMed ID: 17889677
[TBL] [Abstract][Full Text] [Related]
9. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Chu S; Li L; Singh H; Bhatia R
Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
[TBL] [Abstract][Full Text] [Related]
10. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
11. Distinguishing between proliferating nodal lymphoid blasts in chronic myelogenous leukemia and non-Hodgkin lymphoma: report of three cases and detection of a bcr/abl fusion signal by single-cell analysis.
Yashima-Abo A; Satoh T; Abo T; Aoki Y; Kowata S; Ito S; Ishida Y; Fujiwara H; Maesawa C; Masuda T
Pathol Int; 2005 May; 55(5):273-9. PubMed ID: 15871725
[TBL] [Abstract][Full Text] [Related]
12. Insights into JAK2-V617F mutation in CML.
Bocchia M; Vannucchi AM; Gozzetti A; Guglielmelli P; Poli G; Crupi R; Defina M; Bosi A; Francesco L
Lancet Oncol; 2007 Oct; 8(10):864-6. PubMed ID: 17913657
[No Abstract] [Full Text] [Related]
13. Philadelphia negative BCR-ABL positive chronic myeloid leukemia mimicking juvenile chronic myeloid leukemia in a 2-year-old child.
Mahon FX; Labouyrie E; Aurich-Costa J; Dastugue N; Micheau M; Bady C; Perel Y; Bilhou-Nabera C; Reiffers J; Bernard P
Leuk Lymphoma; 1997 Aug; 26(5-6):615-9. PubMed ID: 9389369
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
15. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
Jallades L; Hayette S; Tigaud I; Johnston A; Coiffier B; Magaud JP; Ffrench M
Leuk Res; 2008 Oct; 32(10):1608-10. PubMed ID: 18448166
[TBL] [Abstract][Full Text] [Related]
16. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
McCarron SL; Haslam K; Crampe M; Langabeer SE
Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
[No Abstract] [Full Text] [Related]
17. Insights into JAK2-V617F mutation in CML.
Büsche G; Hussein K; Bock O; Kreipe H
Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
[No Abstract] [Full Text] [Related]
18. Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.
Lund HL; Hughesman CB; McNeil K; Clemens S; Hocken K; Pettersson R; Karsan A; Foster LJ; Haynes C
Anal Bioanal Chem; 2016 Feb; 408(4):1079-94. PubMed ID: 26631023
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of lymphoplasmacytic lymphoma in a chronic myeloid leukemia patient following long-term treatment with tyrosine kinase inhibitors: A case report.
Lee CH; Jeon SY; Yhim HY; Jang KY; Kwak JY
Medicine (Baltimore); 2020 May; 99(19):e19962. PubMed ID: 32384445
[TBL] [Abstract][Full Text] [Related]
20. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.
Cirmena G; Aliano S; Fugazza G; Bruzzone R; Garuti A; Bocciardi R; Bacigalupo A; Ravazzolo R; Ballestrero A; Sessarego M
Cancer Genet Cytogenet; 2008 Jun; 183(2):105-8. PubMed ID: 18503828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
